 |
Plasminogen Activator Inhibitor 1 - Metabolism
Research News and Information
Definition of 'Plasminogen Activator Inhibitor 1'A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators. Common names: Plasminogen Activator Inhibitor 1; PAI-1; Type 1 Plasminogen Activator Inhibitor |
Monday, November 23, 2009
Requirement of a dynein light chain in TGFbeta/Smad3 signaling.
29 Nov 2009 
We have previously reported that the dynein light chain (DLC) km23-1 is required for Smad2-dependent TGFbeta signaling. Here we describe another member of the km23/DYNLRB/LC7/robl family of DLCs, termed km23-2, which is also involved in TGFbeta ... Read more...
12 Sep 2009 Obesity is a risk factor for breast cancer and is associated with increased plasma concentrations of free fatty acids (FFAs). We and others have demonstrated that FFA induces plasminogen activator inhibitor-1 (PAI-1) expression in a variety of ... Read more...
30 Aug 2009 Plasminogen activator inhibitor type I (PAI-1) is a marker of the fibrinolytic system and serves as a possible predictor for hepatic metabolic syndromes. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, is a drug ... Read more...
Latest indexed articles for 'Plasminogen Activator Inhibitor 1 - Metabolism'
These are the very latest articles for this heading:
- Requirement of a dynein light chain in TGFbeta/Smad3 signaling. 29 Nov 2009
- Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
13 Sep 2009 - Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4. 12 Sep 2009
- Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. 30 Aug 2009
- Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism. 30 Aug 2009
- Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis. 20 Aug 2009
- Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. 3 Aug 2009
- The peritoneal fibrinolytic response to conventional and laparoscopic colonic surgery. 30 Jul 2009
- Regulation of plasminogen activator inhibitor 1 expression in human osteoarthritic chondrocytes by fluid shear stress: role of protein kinase Calpha. 30 Jul 2009
- Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. 20 Jul 2009
- [Study of the genetic markers of thrombosis in hypertensive patients of the native population in the Republic of Mordovia] 29 Jun 2009
- Expression profiling of stationary and migratory intestinal epithelial cells after in vitro wounding: restitution is accompanied by cell differentiation. 29 Jun 2009
- PRDX6 attenuates oxidative stress- and TGFbeta-induced abnormalities of human trabecular meshwork cells. 29 Jun 2009
- Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. 29 Jun 2009
- Activated platelets increase fibrinolysis of mesenchymal progenitor cells. 29 Jun 2009
- Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis. 16 Jun 2009
- Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. 14 Jun 2009
- Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. 13 Jun 2009
- Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro. Jun 2009
- Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. 31 May 2009
See a longer list of these articles.
Technical information about 'Plasminogen Activator Inhibitor 1'
Definition: A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators.
Registry Number: 0
Descriptor UI: D017395
Alternative terms: Plasminogen Activator Inhibitor 1; PAI-1; Type 1 Plasminogen Activator Inhibitor;
Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;
Pharmacological Action: Serine Proteinase Inhibitors;
Tree Number: D12.776.124.125.640; D12.776.872.695.500; D23.119.797;
Online Note: use PLASMINOGEN INACTIVATORS to search PAI-1 1990-92
History Note: 93; PAI-1 was see PLASMINOGEN INACTIVATORS 1990-92
Technical Notes: a serpin; DF: note short X ref